A study focused on gC1qR-directed mAb therapy for mesothelioma indicated that mAb 60.11, directed against amino acids 76–93 of the C1q binding domain, significantly reduced tumor growth and aberrant angiogenesis in vivo. Here, C1QBP is linked to neoplasm.